BC179 Against Alcohol-Induced Damage

Launched by WECARE PROBIOTICS CO., LTD. · Mar 25, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a probiotic called BC179 to see if it can help reduce the amount of alcohol absorbed by the body and lower health risks related to drinking. Researchers will measure how well this probiotic works by asking participants about their hangover experiences after drinking alcohol. The trial is not yet recruiting participants, but when it starts, it will be open to men and women aged 18 to 75 who have a history of heavy drinking—defined as consuming at least 40 grams of alcohol per day for over a year.

To participate, individuals will need to have a body mass index (BMI) between 18 and 25 and must agree to follow the study rules. They should not have certain health conditions, like liver disease or severe allergies, and cannot be pregnant, breastfeeding, or planning to become pregnant during the study. Participants will take the probiotic and provide feedback on their experiences, helping researchers understand its effects. This study aims to find a safer way to manage alcohol consumption and its effects on health.

Gender

ALL

Eligibility criteria

• * Inclusion Criteria:
• • 1. A history of long-term heavy alcohol consumption, equivalent to ethanol intake ≥40g/day for over 1 year. The conversion formula is: ethanol (g) = volume of ethanol-containing beverage (mL) × ethanol content (%) × 0.8 (specific gravity of ethanol);
• • 2. Body Mass Index (BMI) between 18kg/m² and 25kg/m²; Voluntarily signed a written informed consent form, agreeing to participate in this study;
• • 3. Agreed to comply with the study protocol and restrictions;
• • 4. Subjects (including male participants) have no plans for conception from 14 days prior to screening until 6 months after the end of the trial and voluntarily agree to use effective contraception.
• * Exclusion Criteria:
• • 1. Patients with various types of viral hepatitis, autoimmune liver disease, drug-induced liver damage, vascular liver disease, genetic metabolic liver disease, or primary liver cancer;
• • 2. Individuals who have recently consumed substances with similar functions to the tested product, potentially affecting the study results;
• • 3. Patients with severe allergies or immune deficiencies;
• • 4. Pregnant, breastfeeding, or women with plans for pregnancy;
• • 5. Individuals with severe diseases of vital organs such as cardiovascular, pulmonary, hepatic, renal conditions, or those with diabetes, severe thyroid disorders, metabolic diseases, malignant tumors, or severe immune system disorders;
• • 6. Individuals who have used antibiotics within the past two weeks;
• • 7. Participants who did not comply with the required consumption of the tested product or missed follow-ups, making it impossible to evaluate the effectiveness;
• • 8. Other participants deemed unsuitable by the researchers.